Healthcare
Spero Therapeutics, Inc.(SPRO)
Live Price
Offline$2.28
+8.06% today
1Y Change
-22.18%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $140.00M
- Revenue Growth
- +24.3%
- EPS Growth
- +111.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spero Therapeutics, Inc. (SPRO) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $2.28 and down 22.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +24.3%, EPS growth of +111.8%, a dividend yield of 0.0%. What stands out right now is revenue +24.3%, EPS +111.8%, free cash flow +46.2% with operating margin -0.0% and ROIC -0.0%. Valuation is more restrained than many high-expectation growth names at P/E 16.2 and price/sales 2.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SPRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+24.3% vs +7.6% peer median
Operating Margin
Below sector median
-0.0% vs +19.4% peer median
P/E
Below sector median
16.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +24.3% and EPS at +111.8%, with operating margin around -0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +13.1% | +7.8% | +10.7% |
2026 Mar 26, 2026 | +365.0% | -1.7% | +2.5% | +15.6% |
2025 Nov 13, 2025 | +48.0% | -1.2% | -7.4% | -4.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SPRO Max Drawdown
-39.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SPRO and SPY.
Company Overview
Spero Therapeutics, Inc.
NASDAQ Global Select
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Esther Rajavelu
- IPO Date
- Nov 2, 2017
- Employees
- 32
- Street Address
- 675 Massachusetts Avenue
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 242 1600
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 16.2
- EV/EBITDA
- 19.4
- Price/Sales
- 2.4
- Price/Book
- 2.4
Growth
- Revenue
- +24.3%
- EPS
- +111.8%
- Free Cash Flow
- +46.2%
Profitability
- Gross Margin
- 77.5%
- Operating Margin
- -0.0%
- Net Margin
- 14.2%
- ROE
- 22.5%
- ROIC
- -0.0%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 7.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.